Socially-Integrated Transdisciplinary HIV Prevention

AIDS and Behavior

Volumn 18, Issue 10, 2014, Pages 1821-1834

  Friedman, Samuel R ^a   Downing, Martin J ^a   Smyrnov, Pavlo ^b,c   Nikolopoulos, Georgios ^a,d   Schneider, John A ^e,f   Livak, Britt ^f   Magiorkinis, Gkikas ^g,h   Slobodianyk, Liudmyla ^b,i   Vasylyeva, Tetyana I ^b   Paraskevis, Dimitrios ^h   Psichogiou, Mina ^h,j   Sypsa, Vana ^h   Malliori, Melpomeni M ^h,k   Hatzakis, Angelos ^h  

^a NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^b The International HIV/AIDS Alliance in Ukraine   (Ukraine)

^c NATIONAL UNIVERSITY OF KYIV MOHYLA ACADEMY   (Ukraine)

^d Hellenic Centre for Disease Control and Prevention   (Greece)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ WHO Country Office in Ukraine   (Ukraine)

^j UNIVERSITY OF ATHENS   (Greece)

^k Organization Against Drugs (OKANA)   (Greece)

more..

Author keywords

Cascade; Combination prevention; Community; HIV prevention; Social networks; Socially integrated intervention; Treatment as prevention

Indexed keywords

ATTITUDE TO HEALTH; CONDOM; HEALTH CARE DISPARITY; HEALTH CARE QUALITY; HEALTH EDUCATION; HIGH RISK BEHAVIOR; HIV INFECTIONS; HUMAN; INTERDISCIPLINARY COMMUNICATION; ORGANIZATION AND MANAGEMENT; PHYLOGENY; PROGRAM EVALUATION; PSYCHOLOGY; PUBLIC HEALTH; RISK REDUCTION; STATISTICS AND NUMERICAL DATA; TIME; TOTAL QUALITY MANAGEMENT; TRANSMISSION; UTILIZATION; VIRUS LOAD;

CONDOMS; HEALTH EDUCATION; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTHCARE DISPARITIES; HIV INFECTIONS; HUMANS; INTERDISCIPLINARY COMMUNICATION; PHYLOGENY; PROGRAM EVALUATION; PUBLIC HEALTH; QUALITY IMPROVEMENT; QUALITY OF HEALTH CARE; RISK REDUCTION BEHAVIOR; RISK-TAKING; TIME FACTORS; VIRAL LOAD;

EID: 84919482390     PISSN: 10907165     EISSN: 15733254     Source Type: Journal    
DOI: 10.1007/s10461-013-0643-5     Document Type: Article

References (131)

1. Auerbach DM, Darrow WW, Jaffe HW, Curran JW. Cluster of cases of the acquired immune deficiency syndrome. Patients linked by sexual contact. Am J Med. 1984;76:487–92.
2. Friedman SR, Bolyard M, Mateu-Gelabert P, et al. Some data-driven reflections on priorities in AIDS network research. AIDS Behav. 2007;11(5):641–51.
3. Friedman SR, Neaigus A, Jose B, et al. Sociometric risk networks and risk for HIV infection. Am J Public Health. 1997;87(8):1289–96.
4. Potterat JJ, Phillips-Plummer L, Muth SQ, et al. Risk network structure in the early epidemic phase of HIV transmission in Colorado Springs. Sex Transm Infect. 2002;78(Suppl 1):i159–63.
5. Rothenberg RB, Potterat JJ, Woodhouse DE, et al. Social network dynamics and HIV transmission. AIDS. 1998;12(12):1529–36.
6. Ambrosioni J, Junier T, Delhumeau C, et al. Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections. AIDS. 2012;26(16):2079–86.
7. Brenner BG, Roger M, Routy JP, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195(7):951–9.
8. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. N Engl J Med. 2011;364(20):1943–54.
9. Hughes JP, Baeten JM, Lingappa JR, et al. Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis. 2012;205(3):358–65.
10. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403–9.
11. Friedman SR, Kottiri BJ, Neaigus A, Curtis R, Vermund SH, Des Jarlais DC. Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population-group saturation. Am J Epidemiol. 2000;152(10):913–22.
12. Khan B, Dombrowski K, Saad M, McLean K, Friedman S. Network firewall dynamics and the subsaturation stabilization of HIV. Discret Dyn Nat Soc. 2013;. doi:10.1155/2013/720818.
13. Friedman SR, Neaigus A, Jose B, et al. Networks, norms, and solidaristic/altruistic action against AIDS among the demonized. Sociol Focus. 1999;32:127–42.
14. Friedman SR, Bolyard M, Maslow C, Mateu-Gelabert P, Sandoval M. Harnessing the power of social networks to reduce HIV risk. Focus. 2005;20(1):5–6.
15. Friedman SR, Cooper HL, Osborne AH. Structural and social contexts of HIV risk among African-Americans. Am J Public Health. 2009;99(6):1002–8.
16. Friedman SR, Jose B, Neaigus A, et al. Multiple racial/ethnic subordination and HIV among drug injectors. In: Singer M, editor. The political economy of AIDS. Amityville: Baywood Press; 1998.
17. Friedman SR, Maslow C, Bolyard M, Sandoval M, Mateu-Gelabert P, Neaigus A. Urging others to be healthy: “intravention” by injection drug users as a community prevention goal. AIDS Educ Prev. 2004;16(3):250–63.
18. Friedman SR, Wiebel W, Jose B, Levin L. Changing the culture of risk. In: Brown BS, Beschner GM, National AIDS Research Consortium, editors. Handbook on risk of AIDS: injection drug users and sexual partners. Westport: Greenwood Press; 1993.
19. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372(9639):669–84.
20. Kurth AE, Celum C, Baeten JM, Vermund SH, Wasserheit JN. Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep. 2011;8(1):62–72.
21. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378(9787):269–78.
22. US National HIV/AIDS Strategy. http://www.aids.gov/federal-resources/national-hiv-aids-strategy/overview/ (2013). Accessed 8 Aug 2013.
23. Vermund SH, Hayes RJ. Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep. 2013;10(2):169–86.
24. Centers for Disease Control and Prevention. Effect of antiretroviral therapy on risk of sexual transmission of HIV infection and superinfection. http://www.cdc.gov/hiv/prevention/research/art (2009). Accessed 2 Aug 2013.
25. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
26. The U.S. President’s emergency plan for AIDS relief: five-year strategy. http://www.pepfar.gov/strategy/ (2009). Accessed 2 Aug 2013.
27. Latkin C, Weeks MR, Glasman L, Galletly C, Albarracin D. A dynamic social systems model for considering structural factors in HIV prevention and detection. AIDS Behav. 2010;14(Suppl 2):222–38.
28. Kalichman SC, Cherry C, Kalichman MO, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health. 2011;101(3):531–8.
29. Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.
30. Cohen SM, Van Handel MM, Branson BM, et al. Vital signs: HIV prevention through care and treatment. MMWR. 2011;60(47):1618–23.
31. Centers for Disease Control and Prevention. CDC Fact Sheet. HIV in the United States, the stages of care. http://www.cdc.gov/nchhstp/newsroom/docs/2012/Stages-of-CareFactSheet-508.pdf (2012). Accessed 30 Aug 2013.
32. Janz NK, Becker MH. The health belief model: a decade later. Health Educ Q. 1984;11(1):1–47.
33. Wood E, Montanger JS, Bangsberg DR, et al. Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world. AIDS. 2003;17(17):2419–27.
34. Kondilis E, Giannakopoulos S, Gavana M, Ierodiakonou I, Waitzkin H, Benos A. Economic crisis, restrictive policies, and the population’s health and health care: the Greek case. Am J Public Health. 2013;103(6):973–9.
35. Friedman SR, Rossi D, Braine N. Theorizing “Big Events” as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy. 2009;20(3):283–91.
36. Friedman SR, Sandoval M, Mateu-Gelabert, et al. Theory, measurement and hard times: some issues for HIV/AIDS research. AIDS Behav. 2013;17(6):1915–25.
37. Friedman SR, Wainberg MA, Drucker E. Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications. AIDS. 1998;12(16):2089–93.
38. Indyk D, editor. The geometry of care: linking resources, research and community to reduce degrees of separation between HIV treatment and prevention. Philadelphia: Haworth Press, Inc.; 2006.
39. Sumartojo E. Structural factors in HIV prevention: concepts, examples, and implications for research. AIDS. 2000;14(Suppl 1):S3–10.
40. Friedman S, Vasylyeva T, Smyrnov P. Recently-funded transdisciplinary integrated HIV prevention project: overview and challenges. Somatosphere/transcriptions. HIV, Science, and the Social: A collaborative forum for critical enquiry on HIV/AIDS and global health: experiment, ethics, and practice. http://somatosphere.net/transcriptions (2012). Accessed 30 Aug 2013.
41. Hamlyn E, Ewings FM, Porter K, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One. 2012;7(8):e43754.
42. Jarzebowski W, Caumes E, Dupin N, et al. Effect of early syphilis infection on plasma viral load and CD4 cell count in human immunodeficiency virus-infected men: results from the FHDH-ANRS CO4 cohort. Arch Intern Med. 2012;172(16):1237–43.
43. Modjarrad K, Vermund SH. Effect of treating co-infections on HIV-1 viral load: a systematic review. Lancet Infect Dis. 2010;10(7):455–63.
44. Chibo D, Kaye M, Birch C. HIV transmissions during seroconversion contribute significantly to new infections in men who have sex with men in Australia. AIDS Res Hum Retroviruses. 2012;28(5):460–4.
45. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med. 2008;5(3):e50. doi:10.1371/journal.pmed.0050050.
46. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687–93.
47. Pinkerton SD. Probability of HIV transmission during acute infection in Rakai, Uganda. AIDS Behav. 2008;12(5):677–84.
48. Cohen MS, Gay CL, Busch MP, Hecht FM. The detection of acute HIV infection. J Infect Dis. 2010;202(Suppl 2):S270–7.
49. Duong YT, Qiu M, De AK, et al. Detection of recent HIV-1 infection using a new limiting-antigen avidity assay: potential for HIV-1 incidence estimates and avidity maturation studies. PLoS One. 2012;7(3):e33328. doi:10.1371/journal.pone.0033328.
50. Deeks SG, Gange SJ, Kitahata MM, et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis. 2009;49(10):1582–90.
51. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–26.
52. Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis. 2009;49(10):1570–8.
53. Pantazis N, Touloumi G, Vanhems P, et al. The effect of antiretroviral treatment of different durations in primary HIV infection. AIDS. 2008;22(18):2441–50.
54. SPARTAC Trial Investigators, Fidler S, Porter K, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368(3):207–17.
55. Sáez-Cirión A, Bacchus C, Hocqueloux L, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 2013;9(3):e1003211. doi:10.1371/journal.ppat.1003211.
56. Bastard M, Nicolay N, Szumilin E et al. Adults receiving HIV care before the start of antiretroviral therapy in sub-Saharan Africa: patient outcomes and associated risk factors. J Acquir Immune Defic Syndr. 2013. doi:10.1097/QAI.0b013e3182a61e8d.
57. Mugavero MJ, Amico KR, Horn T, Thompson MA. The state of engagement in HIV care in the United States: from cascade to continuum to control. Clin Infect Dis. 2013;57(8):1164–71.
58. Bogart LM, Chetty S, Giddy J, et al. Barriers to care among people living with HIV in South Africa: contrasts between patient and healthcare provider perspectives. AIDS Care. 2013;25(7):843–53.
59. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS. 2012;26(16):2059–67.
60. Kempf M-C, McLeod J, Boehme AK, et al. A qualitative study of the barriers and facilitators to retention-in-care among HIV-positive women in the rural southeastern United States: implications for targeted interventions. AIDS Patient Care STDS. 2010;24(8):515–20.
61. Pellowski JA. Barriers to care for rural people living with HIV: a review of domestic research and health care models. J Assoc Nurses AIDS Care. 2013;24(5):422–37.
62. Posse M, Baltussen R. Barriers to access to antiretroviral treatment in Mozambique, as perceived by patients and health workers in urban and rural settings. AIDS Patient Care STDS. 2009;23(10):867–75.
63. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO Press; 2013.
64. Rajabiun S, Mallinson K, McCoy K et al. “Getting me back on track”: the role of outreach interventions in engaging and retaining people living with HIV/AIDS in medical care. AIDS Patient Care STDS. 2007;21(S1):S20–9.
65. Rachlis B, Ahmad F, van Lettow M, et al. Using concept mapping to explore why patients become lost to follow up from an antiretroviral therapy program in the Zomba district of Malawi. BMC Health Serv Res. 2013;13:210.
66. Pecoraro A, Royer-Malvestuto C, Rosenwasser B et al. Factors contributing to dropping out from and returning to HIV treatment in an inner city primary care HIV clinic in the United States. AIDS Care. 2013. doi:10.1080/09540121.2013.772273.
67. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27(16):2559–66.
68. Schneider J, Kaplan SH, Greenfield S, Li W, Wilson IB. Better physician-patient relationships are associated with higher reported adherence to antiretroviral therapy in patients with HIV infection. J Gen Intern Med. 2004;19(11):1096–103.
69. Scanlon ML, Vreeman RC. Current strategies for improving access and adherence to antiretroviral therapies in resource-limited settings. HIV AIDS (Auckl). 2013;5:1–17.
70. Maulsby C, Millett G, Lindsey K et al. HIV among black men who have sex with men (MSM) in the United States: a review of the literature. AIDS Behav. 2013. doi:10.1007/s10461-013-0476-2.
71. Magnus M, Herwehe J, Murtaza-Rossini M, et al. Linking and retaining HIV patients in care: the importance of provider attitudes and behaviors. AIDS Patient Care STDS. 2013;27(5):297–303.
72. Ammassari A, Trotta MP, Murri R et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr. 2002;31(S3):S123–7.
73. Ekstrand M, Crosby M, DeCarlo P. What is the role of adherence in HIV treatment? (Fact sheet). San Francisco: Center for AIDS Prevention Studies (CAPS) and the AIDS Research Institute, University of California; 2003.
74. Grierson J, Koelmeyer RL, Smith A, Pitts M. Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians. HIV Med. 2011;12(9):562–9.
75. Wasti SP, van Teijlingen E, Simkhada P, et al. Factors influencing adherence to antiretroviral treatment in Asian developing countries: a systematic review. Trop Med Int Health. 2012;17(1):71–81.
76. Nokes K, Johnson MO, Webel A, et al. Focus on increasing treatment self-efficacy to improve human immunodeficiency virus treatment adherence. J Nurs Scholarsh. 2012;44(4):403–10.
77. Johnson MO, Sevelius JM, Dilworth SE, Saberi P, Neilands TB. Preliminary support for the construct of health care empowerment in the context of treatment for human immunodeficiency virus. Patient Prefer Adherence. 2012;6:395–404.
78. Chicago Black Gay Caucus. Resource directory. www.chiblackgaycaucus.org. Accessed 6 Aug 2013.
79. Positively Aware. The HIV Treatment Journal of Test Positive Aware Network. www.positivelyaware.com. Accessed 8 Aug 2013.
80. Enriquez M, Farnan R, Neville S. What experienced HIV-infected lay peer educators working in midwestern U.S. HIV medical care settings think about their role and contributions to patient care. AIDS Patient Care STDS. 2013;27(8):474–80.
81. Rhodes SD, Foley KL, Zometa CS, Bloom FR. Lay health advisor interventions among Hispanics/Latinos: a qualitative systematic review. Am J Prev Med. 2007;33(5):418–27.
82. Rhodes SD, Kelley C, Simán F, et al. Using community-based participatory research (CBPR) to develop a community-level HIV prevention intervention for Latinas: a local response to a global challenge. Womens Health Issues. 2012;22(3):e293–301.
83. Vissman AT, Eng E, Aronson RE, et al. What do men who serve as lay health advisers really do?: immigrant Latino men share their experiences as navegantes to prevent HIV. AIDS Educ Prev. 2009;21(3):220–32.
84. Lichtenstein B, Bachmann LH. Staff affirmations and client criticisms: staff and client perceptions of quality of care at sexually transmitted disease clinics. Sex Transm Dis. 2005;32(5):281–5.
85. Solarz AL, editor. Lesbian health: current assessment and directions for the future. Washington, DC: National Academy Press; 1999.
86. Bradford JB, Coleman S, Cunningham W. HIV system navigation: an emerging model to improve HIV care access. AIDS Patient Care STDS. 2007;21(S1):S49–58.
87. Liau A, Crepaz N, Lyles CM, et al. Interventions to promote linkage to and utilization of HIV medical care among HIV-diagnosed persons: a qualitative systematic review, 1996–2011. AIDS Behav. 2013;17(6):1941–62.
88. Horner RD, Salazar W, Geiger J et al. Changing healthcare professionals’ behaviors to eliminate disparities in healthcare: What do we know? How might we proceed? Am J Manag Care. 2004;10:SP12–19.
89. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med. 2003;11(6):185–98.
90. Iwu EN, Holzemer WL. Task shifting of HIV management from doctors to nurses in Africa: clinical outcomes and evidence on nurse self-efficacy and job satisfaction. AIDS Care. 2013. doi:10.1080/09540121.2013.793278.
91. Binford MC, Kahana SY, Altice FL. A systematic review of antiretroviral adherence interventions for HIV-infected people who use drugs. Curr HIV/AIDS Rep. 2012;9(4):287–312.
92. Hart JE, Jeon CY, Ivers LC et al. Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr. 2010;54(2):167–79. Erratum in: J Acquir Immune Defic Syndr. 2011;56(1):e37–8.
93. Schneider JA, Walsh T, Cornwell B, et al. HIV health center affiliation networks of Black men who have sex with men: disentangling fragmented patterns of HIV prevention service utilization. Sex Transm Dis. 2012;39(8):598–604.
94. Quimby E, Friedman SR. Dynamics of Black mobilization against AIDS in New York City. Soc Probl. 1989;36(4):403–15.
95. Cohen C. The Boundaries of Blackness: AIDS and the Breakdown of Black Politics. Chicago: University of Chicago Press; 1999.
96. Lune H. Urban Action Networks: HIV/AIDS and Community Organizing in New York City. New York: Rowman & Littlefield; 2007.
97. Faubion T. Multiplicity of Meaning: Living with HIV/AIDS. In: Pope C, White R, Malow R, editors. HIV/AIDS: global frontiers in prevention/intervention. New York: Routledge, Inc.; 2008.
98. Lindau ST, Makelarski JA, Chin MH, et al. Building community-engaged health research and discovery infrastructure on the south side of Chicago: science in service to community priorities. Prev Med. 2011;52(3–4):200–7.
99. Minkler M, Wallerstein N. Community-based participatory research for health: from process to outcomes. (Google eBook). New York: Wiley; 2011.
100. Jana S, Basu I, Rotheram-Borus MJ, Newman PA. The Sonagachi Project: a sustainable community intervention program. AIDS Educ Prev. 2004;16(5):405–14.
101. Grebe E. The treatment action campaign’s struggle for AIDS treatment in South Africa: coalition-building through networks. J South Afr Stud. 2011;37(4):849–68.
102. Latkin C, Friedman SR, editors. Special issue on drug users as change agents. Subst Use Misuse. 2012;47(5).
103. Des Jarlais DC, Perlis T, Arasteh K, et al. “Informed altruism” and “partner restriction” in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York city, 1990–2001. J Acquir Immune Defic Syndr. 2004;35(2):158–66.
104. Friedman SR, Jose B, Neaigus A, et al. Consistent condom use in relationships between seropositive injecting drug users and sex partners who do not inject drugs. AIDS. 1994;8(3):357–61.
105. Proceedings of the Conference “HIV/AIDS Prevention: Sharing experiences for joint actions”; 2008 Nov 21–22; Kyiv, Ukraine. http://www.hiv-initiative-ukraine.org/uploads/media/Conference_Documentation_EN.pdf. Accessed 8 Aug 2013.
106. Friedman SR, Bolyard M, Maslow C, et al. Dificultades potenciales en la implementación a nivel comunitario de la vacunación contra el HIV: lecciones de la vacunación contra la hepatitis B. Actualizaciones en SIDA. 2007;15:139–47.
107. Ritvo P, Wilson K, Willms D, et al. Vaccines in the public eye. Nat Med. 2005;11(4 Suppl):S20–4.
108. Roberts KJ, Newman PA, Duan N, Rudy ET. HIV vaccine knowledge and beliefs among communities at elevated risk: conspiracies, questions and confusion. J Natl Med Assoc. 2005;97(12):1662–71.
109. Friedman SR, de Jong W, Rossi D, et al. Harm reduction theory: users’ culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users’ groups. Int J Drug Policy. 2007;18(2):107–17.
110. Wohlfeiler D. Structural and environmental HIV prevention for gay and bisexual men. AIDS. 2000;14(Suppl 1):S52–6.
111. Wohlfeiler D, Ellen JM. The limits of behavioral interventions for HIV prevention. In: Cohen L, Chavez V, Chehimi S, editors. Prevention is primary: strategies for community well-being. San Francisco: Jossey-Bass; 2007.
112. Dwyer P, Zeilig L. African struggles today: social movements since independence. Chicago: Haymarket Books; 2012.
113. Friedman SR, Stepherson B, Woods J, Des Jarlais DC, Ward TP. Society, drug injectors, and AIDS. J Health Care Poor Underserved. 1992;3(1):73–89.
114. Friedman SR. Teamster rank and file. New York: Columbia University Press; 1982.
115. Gamson W. Power and discontent. Homewood: The Dorsey Press; 1968.
116. Hodson R. Dignity at work. New York: Cambridge University Press; 2001.
117. Memmi A. The colonizer and the colonized. Boston: Beacon Press; 1991.
118. Scott JC. Domination and the arts of resistance: hidden transcripts. New Haven: Yale University Press; 1990.
119. Auerbach J. Transforming social structures and environments to help in HIV prevention. Health Aff. 2009;28(6):1655–65.
120. Friedman SR, Des Jarlais DC, Ward TP. Social models for changing health-relevant behavior. In: DiClemente R, Peterson J, editors. Preventing AIDS: theories and methods of behavioral interventions. New York: Plenum Press; 1994.
121. Friedman SR, Wypijewska C. Social Science Intervention Models for Reducing HIV Transmission. In: Assessing the Social and Behavioral Science Base for HIV/AIDS Prevention and Intervention: Workshop Summary—Background Papers. Washington, DC: National Academy Press; 1995.
122. Gupta GR, Fisher WF. Revolutionizing the AIDS response: building AIDS resilient communities. aids2031 Social Drivers Working Group Synthesis Paper. 2010. http://www.aids2031.org/pdfs/social%20drivers%20report%201st%20pg_merged.pdf. Accessed 30 Aug 2013.
123. Workshop Committee on the Social and Behavioral Science Base for HIV/AIDS Prevention and Intervention. Assessing the social and behavioral science base for HIV/AIDS prevention and intervention: workshop summary. Washington, DC: National Academy Press; 1995.
124. Paraskevis D, Nikolopoulos G, Tsiara C et al. HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report. Euro Surveill. 2011;16(36):19962.
125. Sypsa V, Paraskevis D, Malliori M et al. Homelessness and other risk factors for HIV infection in the current outbreak among injecting drug users in Athens, Greece. Am J Public Health (in press).
126. Auerbach J, Parkhurst JO, Cáceres C, Keller KE. Addressing social drivers of HIV/AIDS: some conceptual, methodological and evidentiary considerations. aids2031 Social Drivers Working Group Working Paper #24. http://www.aids2031.org/pdfs/aids2031%20social%20drivers%20paper%2024-auerbach%20et%20all.pdf (2009). Accessed 30 Aug 2013.
127. CDC. HIV surveillance: United States, 1981–2008. MMWR 2011;60:689–93.
128. Marks G, Gardner LI, Craw J, Crepaz N. Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS 2010;24:2665–78.
129. Torian LV, Wiewel EW. Continuity of HIV-related medical care, New York City, 2005–2009: do patients who initiate care stay in care? AIDS Patient Care STDS 2011;25:79–88.
130. Hall IH, Mahle KC, Tang T, Li J, Johnson AS, Shouse L. Retention in care of HIV-infected adults and adolescents in 13 U.S. areas. Presented at the National HIV Prevention Conference, Atlanta, GA, August 14–17, 2011.
131. Tripathi A, Youmans E, Gibson JJ, Duffus WA. The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study. AIDS Res Hum Retroviruses 2011;27:751–8.